Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more
Cipla Limited (CIPLA) - Net Assets
Latest net assets as of September 2025: ₹330.25 Billion INR
Based on the latest financial reports, Cipla Limited (CIPLA) has net assets worth ₹330.25 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹401.64 Billion) and total liabilities (₹71.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹330.25 Billion |
| % of Total Assets | 82.22% |
| Annual Growth Rate | 16.51% |
| 5-Year Change | 68.35% |
| 10-Year Change | 163.68% |
| Growth Volatility | 13.28 |
Cipla Limited - Net Assets Trend (2004–2025)
This chart illustrates how Cipla Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cipla Limited (2004–2025)
The table below shows the annual net assets of Cipla Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹312.89 Billion | +16.74% |
| 2024-03-31 | ₹268.03 Billion | +13.03% |
| 2023-03-31 | ₹237.14 Billion | +12.29% |
| 2022-03-31 | ₹211.17 Billion | +13.62% |
| 2021-03-31 | ₹185.86 Billion | +15.75% |
| 2020-03-31 | ₹160.57 Billion | +4.65% |
| 2019-03-31 | ₹153.44 Billion | +5.23% |
| 2018-03-31 | ₹145.82 Billion | +12.32% |
| 2017-03-31 | ₹129.82 Billion | +9.40% |
| 2016-03-31 | ₹118.66 Billion | +8.05% |
| 2015-03-31 | ₹109.82 Billion | +26.70% |
| 2014-03-31 | ₹86.68 Billion | -3.89% |
| 2013-03-31 | ₹90.19 Billion | +18.07% |
| 2012-03-31 | ₹76.38 Billion | +15.17% |
| 2011-03-31 | ₹66.33 Billion | +12.22% |
| 2010-03-31 | ₹59.11 Billion | +35.94% |
| 2009-03-31 | ₹43.48 Billion | +15.78% |
| 2008-03-31 | ₹37.55 Billion | +16.03% |
| 2007-03-31 | ₹32.36 Billion | +63.18% |
| 2006-03-31 | ₹19.83 Billion | +27.65% |
| 2005-03-31 | ₹15.54 Billion | +22.91% |
| 2004-03-31 | ₹12.64 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cipla Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2291.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹287.89 Billion | 92.29% |
| Common Stock | ₹1.62 Billion | 0.52% |
| Other Comprehensive Income | ₹5.50 Billion | 1.76% |
| Other Components | ₹16.93 Billion | 5.43% |
| Total Equity | ₹311.93 Billion | 100.00% |
Cipla Limited Competitors by Market Cap
The table below lists competitors of Cipla Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
InCapta Inc
PINK:INCT
|
$8.34 Billion |
|
ACS Actividades de Construcción y Servicios S.A
PINK:ACSAF
|
$8.35 Billion |
|
Divi's Laboratories Limited
NSE:DIVISLAB
|
$8.37 Billion |
|
Capcom Co. Ltd
PINK:CCOEF
|
$8.38 Billion |
|
Inspur Electronic Info Industr
SHE:000977
|
$8.33 Billion |
|
Manhattan Associates Inc
NASDAQ:MANH
|
$8.32 Billion |
|
Tech Mahindra Limited
NSE:TECHM
|
$8.32 Billion |
|
Federal Realty Investment Trust
NYSE:FRT
|
$8.32 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cipla Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 267,066,300,000 to 311,934,500,000, a change of 44,868,200,000 (16.8%).
- Net income of 52,725,200,000 contributed positively to equity growth.
- Dividend payments of 10,498,300,000 reduced retained earnings.
- Share repurchases of 500,000 reduced equity.
- New share issuances of 500,000 increased equity.
- Other comprehensive income increased equity by 2,617,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹52.73 Billion | +16.9% |
| Dividends Paid | ₹10.50 Billion | -3.37% |
| Share Repurchases | ₹500.00K | -0.0% |
| Share Issuances | ₹500.00K | +0.0% |
| Other Comprehensive Income | ₹2.62 Billion | +0.84% |
| Other Changes | ₹24.20 Million | +0.01% |
| Total Change | ₹- | 16.80% |
Book Value vs Market Value Analysis
This analysis compares Cipla Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 76.02x to 3.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹16.86 | ₹1281.90 | x |
| 2005-03-31 | ₹20.72 | ₹1281.90 | x |
| 2006-03-31 | ₹26.46 | ₹1281.90 | x |
| 2007-03-31 | ₹41.71 | ₹1281.90 | x |
| 2008-03-31 | ₹48.31 | ₹1281.90 | x |
| 2009-03-31 | ₹55.94 | ₹1281.90 | x |
| 2010-03-31 | ₹74.80 | ₹1281.90 | x |
| 2011-03-31 | ₹83.02 | ₹1281.90 | x |
| 2012-03-31 | ₹95.14 | ₹1281.90 | x |
| 2013-03-31 | ₹112.32 | ₹1281.90 | x |
| 2014-03-31 | ₹134.33 | ₹1281.90 | x |
| 2015-03-31 | ₹134.08 | ₹1281.90 | x |
| 2016-03-31 | ₹142.98 | ₹1281.90 | x |
| 2017-03-31 | ₹155.76 | ₹1281.90 | x |
| 2018-03-31 | ₹176.52 | ₹1281.90 | x |
| 2019-03-31 | ₹186.06 | ₹1281.90 | x |
| 2020-03-31 | ₹195.31 | ₹1281.90 | x |
| 2021-03-31 | ₹227.01 | ₹1281.90 | x |
| 2022-03-31 | ₹258.12 | ₹1281.90 | x |
| 2023-03-31 | ₹289.83 | ₹1281.90 | x |
| 2024-03-31 | ₹330.53 | ₹1281.90 | x |
| 2025-03-31 | ₹385.97 | ₹1281.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cipla Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.90%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.34%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.20x
- Recent ROE (16.90%) is above the historical average (15.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 24.26% | 16.65% | 0.83x | 1.76x | ₹1.80 Billion |
| 2005 | 26.36% | 18.78% | 0.84x | 1.68x | ₹2.54 Billion |
| 2006 | 30.64% | 20.97% | 0.84x | 1.74x | ₹4.09 Billion |
| 2007 | 20.63% | 19.42% | 0.78x | 1.36x | ₹3.44 Billion |
| 2008 | 18.67% | 17.48% | 0.70x | 1.53x | ₹3.26 Billion |
| 2009 | 17.73% | 15.54% | 0.72x | 1.58x | ₹3.36 Billion |
| 2010 | 18.32% | 20.20% | 0.73x | 1.24x | ₹4.92 Billion |
| 2011 | 14.84% | 687.15% | 0.02x | 1.29x | ₹3.23 Billion |
| 2012 | 14.98% | 16.30% | 0.75x | 1.22x | ₹3.80 Billion |
| 2013 | 17.13% | 18.66% | 0.71x | 1.29x | ₹6.43 Billion |
| 2014 | 12.85% | 12.24% | 0.85x | 1.24x | ₹3.08 Billion |
| 2015 | 10.93% | 10.41% | 0.72x | 1.46x | ₹1.01 Billion |
| 2016 | 11.81% | 10.04% | 0.64x | 1.83x | ₹2.08 Billion |
| 2017 | 8.02% | 7.02% | 0.68x | 1.68x | ₹-2.48 Billion |
| 2018 | 9.91% | 9.34% | 0.66x | 1.61x | ₹-123.89 Million |
| 2019 | 10.18% | 9.36% | 0.68x | 1.60x | ₹264.72 Million |
| 2020 | 9.81% | 9.05% | 0.72x | 1.50x | ₹-297.80 Million |
| 2021 | 13.12% | 12.58% | 0.76x | 1.37x | ₹5.72 Billion |
| 2022 | 12.08% | 11.59% | 0.80x | 1.30x | ₹4.33 Billion |
| 2023 | 11.97% | 12.42% | 0.77x | 1.26x | ₹4.61 Billion |
| 2024 | 15.43% | 16.14% | 0.78x | 1.23x | ₹14.51 Billion |
| 2025 | 16.90% | 19.34% | 0.73x | 1.20x | ₹21.53 Billion |
Industry Comparison
This section compares Cipla Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cipla Limited (CIPLA) | ₹330.25 Billion | 24.26% | 0.22x | $8.34 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |